Trial Information
Inclusion Criteria:
- treatment-naive patients with B-cell lymphoma
- HBsAg positive at baseline
- treated with rituximab-based immunochemotherapy
- life expectancy of more than 3 months
Exclusion Criteria:
- younger than 18 years old
- HBsAg negative at baseline
- pregnant or lactating women
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis
Outcome Time Frame:
from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy
Safety Issue:
Yes
Principal Investigator
Jun Zhu
Investigator Role:
Principal Investigator
Investigator Affiliation:
Peking University Cancer Hospital & Institute
Authority:
China: Ethics Committee
Study ID:
PKU-2012111304
NCT ID:
NCT01768195
Start Date:
January 2013
Completion Date:
Related Keywords:
- Hepatitis B
- Lymphoma
- Hepatitis B Virus
- Therapeutic Uses
- Antiviral Agents
- rituximab
- Hepatitis
- Hepatitis A
- Hepatitis B